PDF herunterladen
Dtsch Med Wochenschr 2015; 140(06): 428-432
DOI: 10.1055/s-0041-100846
Fachwissen
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Tropheryma whipplei: Erreger verschiedener Infektionen und Pathogen des Morbus Whipple

Tropheryma whipplei: pathogen of Whipple’s disease and more
Verena Moos
1   Medizinische Klinik I, Charité, Campus Benjamin Franklin, Berlin
,
Thomas Schneider
1   Medizinische Klinik I, Charité, Campus Benjamin Franklin, Berlin
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
16. März 2015 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

In den letzten Jahren haben Fortschritte in der Molekularbiologie, Mikrobiologie und Immunologie das Verständnis der Infektion mit Tropheryma whipplei entscheidend verbessert. Eine Infektion mit T. whipplei führt nur selten zum klassischen M. Whipple. Man sollte folgende Entitäten der Infektion bzw. Besiedelung mit T. whipplei unterscheiden: Neben dem klassischen Morbus Whipple, der seltenen chronischen Infektion mit T. whipplei (geschätzte Inzidenz: 1 : 1.000.000), wird T. whipplei sehr viel häufiger im Stuhl von Kindern mit akuter Gastroenteritis, von symptomlosen Ausscheidern oder als Ursache für isolierte Endokarditis nachgewiesen. T. whipplei wurde in den letzten zwei Jahrzehnten besser charakterisiert, durch Einsatz spezieller Kulturtechniken angezüchtet, und sein Genom wurde komplett sequenziert. Interessant ist die Resistenz des Erregers gegen Glutaraldehyd. Der histologische Nachweis mittels PAS-Färbung („Periodic Acid Schiff“) in Dünndarmbiopsien ist nach wie vor die Methode der Wahl zur Diagnose des klassischen M. Whipple. Heute kann mittels PCR oder Immunhistochemie der Erreger spezifischer nachgewiesen werden. Bei isoliertem Organbefall z. B. der Gelenke oder des Zentralnervensystems muss zum Erregernachweis Probenmaterial aus der betroffenen Region herangezogen werden. Die Behandlung ist in den meisten Fällen durch Antibiotika erfolgreich möglich und erste prospektive Behandlungsstudien wurden abgeschlossen. Dennoch kann der neuronale M. Whipple auch heute noch progredient letal verlaufen. Ein Immunrekonstitutionssyndrom (IRIS) kann den Verlauf der Therapie komplizieren und im schlimmsten Fall fatal enden. Daher sollte auf Grund der Komplexität für die Diagnostik und die Therapie des klassischen M. Whipple immer ein spezialisiertes Zentrum konsultiert werden.

Abstract

Within the last years the understanding of infection with Tropheryma whipplei was significantly enhanced by improvement of molecular biology, microbiology and immunology. The following entities of infection or carriage, respectively, with T. whipplei must be differentiated: besides in the context of classical Whipple’s disease (CWD), the rare chronic infection with T. whipplei (estimated incidence: 1 : 1,000,000), T. whipplei can be detected more frequently in stool specimens of children with acute gastroenteritis or asymptomatic carriers, or as a cause of isolated endocarditis. However, infection with T. whipplei only rarely results in CWD. T. whipplei was well characterized, raised in vitro and its genome completely sequenced within the last two decades. Very interesting is the resistance of the agent against glutaraldehyde.The histological detection within duodenal biopsies with „Periodic Acid Schiff“ (PAS) staining still is first choice for the diagnosis of CWD. Today PCR or immunohistochemistry can identify the agent more specifically. In cases of isolated organ manifestations of e. g. joints or central nervous system the agent needs to be identified from specimen from the affected sites. Successful treatment can be achieved in most of the cases by antimicrobial therapy and first prospective treatment trials are published. However, neuronal CWD still can be progressive lethal and an immune reconstitution inflammatory syndrome (IRIS) might complicate the course of treatment and in worst case end fatal. Thus, because of the complexity of the disease a specialised reference centre should be consulted for diagnosis and treatment of CWD.

Schlüsselwörter

Morbus Whipple - Tropheryma whipplei - chronische Diarrhö - Arthritis - Endokarditis - inflammatorisches Immunrekonstitutionssyndrom (IRIS)

Keywords

Whipple’s disease - Tropheryma whipplei - chronic diarrhea - arthritis - endocarditis, immune reconstitution inflammatory syndrome (IRIS)
 

  • Literatur

  • 1 Schneider T, Moos V, Loddenkemper C et al. Whipple’s disease: new aspects of pathogenesis and treatment. Lancet Infect Dis 2008; 8: 179-190
    CrossrefPubMedGoogle Scholar
  • 2 Lagier JC, Lepidi H, Raoult D et al. Systemic Tropheryma whipplei: clinical presentation of 142 patients with infections diagnosed or confirmed in a reference center. Medicine (Baltimore) 2010; 89: 337-345
    CrossrefPubMedGoogle Scholar
  • 3 Dobbins WI. Whipple’s disease. Springfield, IL: Charles C Thomas; 1987
    Google Scholar
  • 4 von Herbay A, Maiwald M, Ditton HJ et al. Histology of intestinal Whipple’s disease revisited. A study of 48 patients. Virchows Arch 1996; 429: 335-343
    PubMedGoogle Scholar
  • 5 Relman DA, Schmidt TM, MacDermott RP et al. Identification of the uncultured bacillus of Whipple’s disease. N Engl J Med 1992; 327: 293-301
    CrossrefPubMedGoogle Scholar
  • 6 Moter A, Schmiedel D, Petrich A et al. Validation of an rpoB gene PCR assay for detection of Tropheryma whipplei: Ten years experience in a national reference laboratory. J Clin Microbiol 2013; DOI: 10.1128/JCM.01703-13.
    PubMedGoogle Scholar
  • 7 Lepidi H, Fenollar F, Gerolami R et al. Whipple’s disease: immunospecific and quantitative immunohistochemical study of intestinal biopsy specimens. Hum Pathol 2003; 34: 589-596
    CrossrefPubMedGoogle Scholar
  • 8 Fenollar F, Fournier PE, Robert C et al. Use of genome selected repeated sequences increases the sensitivity of PCR detection of Tropheryma whipplei. J Clin Microbiol 2004; 42: 401-403
    CrossrefPubMedGoogle Scholar
  • 9 Raoult D, Fenollar F, Rolain JM et al. Tropheryma whipplei in children with gastroenteritis. Emerg Infect Dis 2010; 16: 776-782
    CrossrefPubMedGoogle Scholar
  • 10 Schoniger-Hekele M, Petermann D, Weber B et al. Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers. Appl Environ Microbiol 2007; 73: 2033-2035
    PubMedGoogle Scholar
  • 11 Fenollar F, Mediannikov O, Socolovschi C et al. Tropheryma whipplei bacteremia during fever in rural West Africa. Clin Infect Dis 2010; 51: 515-521
    CrossrefPubMedGoogle Scholar
  • 12 Fenollar F, Trani M, Davoust B et al. Prevalence of asymptomatic Tropheryma whipplei carriage among humans and nonhuman primates. J Infect Dis 2008; 197: 880-887
    CrossrefPubMedGoogle Scholar
  • 13 Feurle GE, Junga NS, Marth T. Efficacy of ceftriaxone or meropenem as initial therapies in Whipple’s disease. Gastroenterology 2010; 138: 478-486
    CrossrefPubMedGoogle Scholar
  • 14 Feurle GE, Moos V, Blaker H et al. Intravenous ceftriaxone, followed by 12 or three months of oral treatment with trimethoprim-sulfamethoxazole in Whipple’s disease. J Infect 2013; DOI: 10.1016/jjinf.2012.12.004.
    PubMedGoogle Scholar
  • 15 Feurle GE, Moos V, Schinnerling K et al. The immune reconstitution inflammatory syndrome in whipple disease: a cohort study. Ann Intern Med 2010; 153: 710-717
    CrossrefPubMedGoogle Scholar
  • 16 Compain C, Sacre K, Puechal X et al. Central nervous system involvement in Whipple disease: clinical study of 18 patients and long-term follow-up. Medicine (Baltimore) 2013; 92: 324-330
    CrossrefPubMedGoogle Scholar
  • 17 Feurle GE, Marth T. An evaluation of antimicrobial treatment for Whipple’s Disease. Tetracycline versus trimethoprim-sulfamethoxazole. Dig Dis Sci 1994; 39: 1642-1648
    CrossrefPubMedGoogle Scholar
  • 18 Whipple GH. A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues. Bull Johns Hopkins Hosp 1907; 18: 382-393
    PubMedGoogle Scholar
  • 19 Paulley JW. A case of Whipple’s disease (intestinal lipodystrophy). Gastroenterology 1952; 22: 128-133
    PubMedGoogle Scholar
  • 20 Yardley JH, Hendrix TR. Combined electron and light microscopy in Whipple’s disease. Demonstration of „bacillary bodies“ in the intestine. Bull Johns Hopkins Hosp 1961; 109: 80-98
    PubMedGoogle Scholar
  • 21 Schoedon G, Goldenberger D, Forrer R et al. Deactivation of macrophages with interleukin-4 is the key to the isolation of Tropheryma whippelii. J Infect Dis 1997; 176: 672-677
    CrossrefPubMedGoogle Scholar
  • 22 Raoult D, Birg ML, La Scola B et al. Cultivation of the bacillus of Whipple’s disease. N Engl J Med 2000; 342: 620-625
    CrossrefPubMedGoogle Scholar
  • 23 Boulos A, Rolain JM, Mallet MN et al. Molecular evaluation of antibiotic susceptibility of Tropheryma whipplei in axenic medium. J Antimicrob Chemother 2005; 55: 178-181
    CrossrefPubMedGoogle Scholar
  • 24 Li W, Fenollar F, Rolain JM et al. Genotyping reveals a wide heterogeneity of Tropheryma whipplei. Microbiology 2008; 154: 521-527
    CrossrefPubMedGoogle Scholar
  • 25 Raoult D, Ogata H, Audic S et al. Tropheryma whipplei Twist: a human pathogenic Actinobacteria with a reduced genome. Genome Res 2003; 13: 1800-1809
    PubMedGoogle Scholar
  • 26 Raoult D, Fenollar F, Birg ML. Culture of T. whipplei from the stool of a patient with Whipple’s disease. N Engl J Med 2006; 355: 1503-1505
    CrossrefPubMedGoogle Scholar
  • 27 Fenollar F, Keita AK, Buffet S et al. Intrafamilial circulation of Tropheryma whipplei, France. Emerg Infect Dis 2012; 18: 949-955
    PubMedGoogle Scholar
  • 28 Keita AK, Bassene H, Tall A et al. Tropheryma whipplei: a common bacterium in rural Senegal. PLoS neglected tropical diseases 2011; 5: e1403
    CrossrefPubMedGoogle Scholar
  • 29 Bousbia S, Papazian L, Auffray JP et al. Tropheryma whipplei in patients with pneumonia. Emerg Infect Dis 2010; 16: 258-263
    CrossrefPubMedGoogle Scholar
  • 30 Lozupone C, Cota-Gomez A, Palmer BE et al. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med 2013; 187: 1110-1117
    CrossrefPubMedGoogle Scholar
  • 31 Geissdorfer W, Moos V, Moter A et al. High frequency of Tropheryma whipplei in culture-negative endocarditis. J Clin Microbiol 2012; 50: 216-222
    CrossrefPubMedGoogle Scholar
  • 32 Moos V, Kunkel D, Marth T et al. Reduced peripheral and mucosal Tropheryma whipplei-specific Th1 response in patients with Whipple’s disease. J Immunol 2006; 177: 2015-2022
    CrossrefPubMedGoogle Scholar
  • 33 Fenollar F, Amphoux B, Raoult D. A paradoxical Tropheryma whipplei western blot differentiates patients with whipple disease from asymptomatic carriers. Clin Infect Dis 2009; 49: 717-723
    CrossrefPubMedGoogle Scholar
  • 34 Moos V, Schneider T. Changing paradigms in Whipple’s disease and infection with Tropheryma whipplei. Eur J Clin Microbiol 2011; 30: 1151-1158
    PubMedGoogle Scholar
  • 35 Martinetti M, Biagi F, Badulli C et al. The HLA alleles DRB1*13 and DQB1*06 are associated to Whipple’s disease. Gastroenterology 2009; 136: 2289-2294
    CrossrefPubMedGoogle Scholar
  • 36 Biagi F, Badulli C, Feurle GE et al. Cytokine genetic profile in Whipple’s disease. Eur J Clin Microbiol 2012; 31: 3145-3150
    CrossrefPubMedGoogle Scholar
  • 37 von Herbay A, Otto HF, Stolte M et al. Epidemiology of Whipple’s disease in Germany. Analysis of 110 patients diagnosed in 1965–95. Scand J Gastroenterol 1997; 32: 52-57
    CrossrefPubMedGoogle Scholar
  • 38 Mahnel R, Kalt A, Ring S et al. Immunosuppressive therapy in Whipple’s disease patients is associated with the appearance of gastrointestinal manifestations. Am J Gastroenterol 2005; 100: 1167-1173
    CrossrefPubMedGoogle Scholar
  • 39 Lagier JC, Fenollar F, Lepidi H et al. Treatment of classic Whipple’s disease: from in vitro results to clinical outcome. J Antimicrob Chemother 2014; 69: 219-227
    CrossrefPubMedGoogle Scholar